Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares stood at 2.09 million during the last session, with the company’s beta value hitting 0.83. At the close of trading, the stock’s price was $2.44, to imply a decrease of -3.94% or -$0.1 in intraday trading. The ALLO share’s 52-week high remains $5.78, putting it -136.89% down since that peak but still an impressive 17.62% since price per share fell to its 52-week low of $2.01. The company has a valuation of $510.23M, with an average of 1.58 million shares in intraday trading volume over the past 10 days and average of 1.81 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Allogene Therapeutics Inc (ALLO), translating to a mean rating of 1.61. Of 6 analyst(s) looking at the stock, 0 analyst(s) give ALLO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.32.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
After registering a -3.94% downside in the last session, Allogene Therapeutics Inc (ALLO) has traded red over the past five days. The 5-day price performance for the stock is -14.08%, and -10.29% over 30 days. With these gigs, the year-to-date price performance is -23.99%. Short interest in Allogene Therapeutics Inc (NASDAQ:ALLO) saw shorts transact 38.51 million shares and set a 19.57 days time to cover.
The extremes give us $7 and $55 for target low and target high price respectively. As such, ALLO has been trading -2154.1% off suggested target high and -186.89% from its likely low.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Looking at statistics comparing Allogene Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Allogene Therapeutics Inc (ALLO) shares are -15.57% down over the last 6 months, with its year-to-date growth rate higher than industry average at 29.85% against 17.50%. Revenue is forecast to grow 13.50% this quarter before jumping 33.30% for the next one. The rating firms project that company’s revenue will shrink -36.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is 10k. Meanwhile, for the current quarter, a total of 14 analyst(s) estimate revenue growth to 10k.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 22.18% for the past 5-year period. While 2024 is set for a 34.09% return in earnings, projections for the next 5 years are at 1.00% annually.
ALLO Dividends
Allogene Therapeutics Inc has its next earnings report out on 2024-Oct-31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Allogene Therapeutics Inc insiders hold 17.48% of total outstanding shares, with institutional holders owning 83.77% of the shares at 101.52% float percentage. In total, 83.77% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 31.26 million shares (or 18.4816% of shares), all amounting to roughly $72.83 million.
The next major institution holding the largest number of shares is TPG GP A, LLC with 18.72 million shares, or about 11.0663% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $43.61 million.
